NASDAQ, TSX: NVCN VANCOUVER, Nov. 20, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...
Read MoreNASDAQ, TSX: NVCN FDA has granted Breakthrough Device designation to the Neovasc Reducer™ (the "Reducer") for the treatment of refractory angina Reducer implanted in 100th patient in Germany Tiara™ (the "Tiara") featured in live case at the 32nd Annual European Association for Cardio-Thoracic Surgery (EACTS) Meeting...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Nov. 7, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Oct. 22, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...
Read MoreNASDAQ, TSX: NVCN Accompanying editorial comment also published by the journal VANCOUVER, Oct. 16, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX:NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Oct. 10, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Oct. 9, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Oct. 3, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...
Read More